1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,530 | 1,570 | 02.10. | |
| 1,500 | 1,590 | 02.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| INNOCARE PHARMA Aktie jetzt für 0€ handeln | |||||
| 25.09. | Fierce Pharma Asia-Lilly's $3.35B InnoCare deal; Korea's breakthrough; China's 5-year biotech plan | - | FiercePharma | ||
| 25.09. | UBS Positive on INNOCARE -Eli Lilly and Company Collaboration on Innovative Targets | 4 | AASTOCKS | ||
| 24.09. | Lilly Again Looks to China for New Drugs, Paying InnoCare $100M to Start R&D Pact | 7 | MedCity News | ||
| 24.09. | Lilly Wins FDA Nod For Weekly Insulin, Signs $3.25 Billion InnoCare Pact | 4 | Benzinga.com | ||
| 24.09. | Eli Lilly outlays $3.35bn for secretive drug discovery pact with China's InnoCare | 2 | Pharmaceutical Technology | ||
| 24.09. | Eli Lilly and InnoCare Pharma agree on $3.3bn drug research deal | 11 | PMLiVE | ||
| 24.09. | Lilly forges $3.35bn alliance with China's InnoCare | 3 | pharmaphorum | ||
| 24.09. | Chinese Cancer Drug Developer InnoCare, Eli Lilly Ink Deal Worth up to USD3.35 Billion | 6 | Yicai Global | ||
| 24.09. | Lilly puts up $100M, plus billions on the backend, to form 5-target deal with InnoCare | 14 | FierceBiotech | ||
| 24.09. | InnoCare Pharma partners with Eli Lilly in drug research deal | 8 | China Daily | ||
| 24.09. | INNOCARE Forms Strategic Research Collaboration and Licensing Agreement With Eli Lilly and Company for New Drug Development; Shares Slump 10% in Afternoon | 10 | AASTOCKS | ||
| 24.09. | INNOCARE Reaches Strategic Research Collaboration and Licensing Agreement With Eli Lilly and Company for New Drug Development | 7 | AASTOCKS | ||
| 24.09. | InnoCare inks licensing deal with Eli Lilly worth up to $3.35B | 8 | Seeking Alpha | ||
| 24.09. | InnoCare Pharma: InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines | 249 | GlobeNewswire (Europe) | BEIJING, Sept. 24, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today... ► Artikel lesen | |
| 24.09. | INNOCARE (09969): INSIDE INFORMATION ANNOUNCEMENT - STRATEGIC RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH ELI LILLY AND COMPANY | 1 | HKEx | ||
| 22.09. | INNOCARE (09969): INTERIM REPORT 2026 | - | HKEx | ||
| 17.09. | INNOCARE (09969): NEXT DAY DISCLOSURE RETURN - CHANGES IN ISSUED SHARE CAPITAL | - | HKEx | ||
| 09.09. | InnoCare Pharma: InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China | 373 | GlobeNewswire (Europe) | BEIJING, Sept. 08, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today... ► Artikel lesen | |
| 04.09. | InnoCare Pharma returns to profit on strong drug sales | 2 | China Daily | ||
| 28.08. | China's InnoCare Pharma Turns a Profit in First Half Due to Surging Overseas Licensing Revenue | 4 | Yicai Global |
1 2 3 4 5 Weiter >>
87 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 44,940 | -1,01 % | 90 Milliarden US-Dollar bis 2030: Wie Bayer, Mesoblast und NurExone regenerative Medizin unterschiedlich entwickeln | ||
| NOVO NORDISK | 33,210 | -0,48 % | Novo Nordisk gerät trotz GLP-1 unter Druck - warum Eli Lilly und Co. schon Milliarden in neue Plattformen investieren | ||
| PFIZER | 24,735 | +0,18 % | Litfulo and tilrekimig data bolster Pfizer's immunology plans | ||
| MERCK KGAA | 136,90 | +1,82 % | Merck Aktie | Wichtige Durchschnittslinien durchbrochen | Analyse | ||
| GILEAD SCIENCES | 128,68 | +0,09 % | Assembly Biosciences: Herpes-Countdown mit Gilead | ||
| AURORA CANNABIS | 3,518 | +0,86 % | Aurora Cannabis: Beschwerde bringt den Deal ins Wanken | ||
| SANOFI | 71,08 | -0,03 % | Laufende Fusionskontrollverfahren: Sanofi, Paris/FR; Erwerb eines Minderheitsanteils an der Cheplapharm SE (Gemeinschaftsunternehmen mit der Braun Invest Holding GmbH, Greifswald) | Datum der Anmeldung:24.09.2026Aktenzeichen:B3-102/26Unternehmen:Sanofi, Paris/FR; Erwerb eines Minderheitsanteils an der Cheplapharm SE (Gemeinschaftsunternehmen mit der Braun Invest Holding GmbH, Greifswald)Produktmärkte:Arzneimittel... ► Artikel lesen | |
| GSK | 20,870 | -1,04 % | JEFFERIES stuft GSK auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für GSK mit einem Kursziel von 2500 Pence auf "Buy" belassen. B7H3-Antikörper seien eine der am meisten unterschätzten Chancen... ► Artikel lesen | |
| ABBVIE | 231,00 | -0,35 % | AbbVie To Present New Dermatology Data At 2026 EADV Congress | WASHINGTON (dpa-AFX) - AbbVie (ABBV) said it will present new clinical and real-world data across its dermatology portfolio at the 2026 European Academy of Dermatology and Venereology (EADV)... ► Artikel lesen | |
| ELI LILLY | 1.019,20 | +0,33 % | Eli Lilly's Jaypirca gains additional indication for untreated leukemia, lymphoma | ||
| CANOPY GROWTH | 0,780 | +0,72 % | Canopy Growth Corporation: Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany | Mr. Blöte's appointment strengthens Canopy Growth's commercial leadership as it drives growth across its European medical cannabis businessCanopy Growth Corporation ("Canopy Growth", "our", "we" or... ► Artikel lesen | |
| MERCK & CO | 128,18 | 0,00 % | AstraZeneca-Summit, Novo-Hengrui, Merck-Fierce Pharma Asia | ||
| ASTRAZENECA | 139,30 | 0,00 % | Summit to Pair with AstraZeneca, Daiichi Sankyo to Evaluate Ivonescimab as Combination Therapy | ||
| TILRAY BRANDS | 3,215 | +0,31 % | Tilray Brands, Inc.: BrewDog Builds Momentum for Next Growth Chapter with Expanded Senior Leadership Team | New appointments strengthen marketing, hospitality, category, and international commercial leadership as BrewDog advances long-term growth under Tilray BrandsELLON, Scotland and LONDON, Sept. 28, 2026... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 54,11 | -0,39 % | Dividendenbekanntmachungen (02.10.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACME UNITED CORPORATION US0048161048 0,16 USD 0,1423 EUR ALICO INC US0162301040 0,05 USD 0,0444 EUR ATN INTERNATIONAL INC US00215F1075 0... ► Artikel lesen |
INNOCARE PHARMA LTD gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -7,98 % bei einem Aktienkurs von 1,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INNOCARE PHARMA LTD finden Sie auf Wallstreet Online.